Boston Scientific is counting on its interventional cardiology and peripheral interventions businesses to lead it back to revenue growth in 2021.
“Our 2020 financials are clearly a negative outlier to our pre-pandemic six-year track record of excellent results,” CEO Michael Mahoney said during the company’s 3 February fourth-quarter earnings call
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?